Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity’s Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics? at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
Afghanistan: The Next Phase takes an in-depth look at the present situation in Afghanistan by placing it in the context of the country's tribal culture, history and demography. It considers its association with Pakistan, with whom it shares not only a long border, but also the Pashtuns, the largest ethnic component in its population and the rise of extremism in many parts of the Sunni world. The country faces an uncertain future as it has yet to develop the institutional structure that could transform it into an inclusive society. This book offers analysis of what the economic future holds for Afghanistan when the United States completes the withdrawal of combat troops at the end of 2014, when the flow of foreign capital that has helped the country is likely to be reduced significantly. The authors propose a formal association of ten to twelve countries to chaperone the country into the future. In the absence of such an arrangement, Afghanistan could once again become a failed state, which would have repercussions around the world.
Little is known about the Moghuls in the book of History. Nevertheless, their impact on the world system and their great feat cannot be swept under the carpet. The Moghuls dynasty were the rulers of most of northern India from the early 16th to the mid-18th century. Prominent among the Moghul rulers was the founder, Bābur, who ruled between 1526–30); followed by his grandson Akbar (r. 1556–1605). As far as Akbar's life history was concerned, his forefathers came from three separate non-Indian ethnic groups: Turks (or Turki), Mongols (or Moguls), and Persians (or Iranians). As a result, his court displayed a blend of Turkic, Mongol, and Iranian traditions in its behaviour and rituals. Emperor Akbar laid the foundations of the Moghul Empire. He was the longest-ruling Moghul but was succeeded by Emperor Jahangir (1605–1627). Emperor Jahangir ruled for only 22 years but expanded on Akbar's imperial legacy while adding his flourishes. He was followed by Shah Jahān and then Aurangzeb, the third son of Shah Jahān. Under Aurangzeb (r. 1658–1707), the empire reached its greatest extent, but his intolerance sowed the seeds for its decline. It broke up under pressure from factional rivalries, dynastic warfare, and the invasion of northern India in 1739 by Nādir Shah. In this book, you will find the period of the reign of all seven Moghuls, who ruled at various times, and learn about their personal life before the Moghul empire, which finally collapsed when the British captured Delhi and Agra - the Moghul empire epicentres.
Little is known about the Moghuls in the book of History. Nevertheless, their impact on the world system and their great feat cannot be swept under the carpet. The Moghuls dynasty were the rulers of most of northern India from the early 16th to the mid-18th century. Prominent among the Moghul rulers was the founder, Bābur, who ruled between 1526–30); followed by his grandson Akbar (r. 1556–1605). As far as Akbar's life history was concerned, his forefathers came from three separate non-Indian ethnic groups: Turks (or Turki), Mongols (or Moguls), and Persians (or Iranians). As a result, his court displayed a blend of Turkic, Mongol, and Iranian traditions in its behaviour and rituals. Emperor Akbar laid the foundations of the Moghul Empire. He was the longest-ruling Moghul but was succeeded by Emperor Jahangir (1605–1627). Emperor Jahangir ruled for only 22 years but expanded on Akbar's imperial legacy while adding his flourishes. He was followed by Shah Jahān and then Aurangzeb, the third son of Shah Jahān. Under Aurangzeb (r. 1658–1707), the empire reached its greatest extent, but his intolerance sowed the seeds for its decline. It broke up under pressure from factional rivalries, dynastic warfare, and the invasion of northern India in 1739 by Nādir Shah. In this book, you will find the period of the reign of all seven Moghuls, who ruled at various times, and learn about their personal life before the Moghul empire, which finally collapsed when the British captured Delhi and Agra - the Moghul empire epicentres.
Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity’s Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
Economic evaluation has become an essential component of clinical trial design to show that new treatments and technologies offer value to payers in various healthcare systems. Although many books exist that address the theoretical or practical aspects of cost-effectiveness analysis, this book differentiates itself from the competition by detailing
Afghanistan: The Next Phase takes an in-depth look at the present situation in Afghanistan by placing it in the context of the country's tribal culture, history and demography. It considers its association with Pakistan, with whom it shares not only a long border, but also the Pashtuns, the largest ethnic component in its population and the rise of extremism in many parts of the Sunni world. The country faces an uncertain future as it has yet to develop the institutional structure that could transform it into an inclusive society. This book offers analysis of what the economic future holds for Afghanistan when the United States completes the withdrawal of combat troops at the end of 2014, when the flow of foreign capital that has helped the country is likely to be reduced significantly. The authors propose a formal association of ten to twelve countries to chaperone the country into the future. In the absence of such an arrangement, Afghanistan could once again become a failed state, which would have repercussions around the world.
This book considers the challenges of building disaster resilience in South Asia – a region that frequently experiences some of the most severe and devastating impacts of disasters. Despite significant work to assist affected communities, many smaller South Asian countries remain particularly vulnerable in terms of fostering disaster resilience. Drawing on examples from Bangladesh, Bhutan, Maldives, Nepal and Sri Lanka, the book offers rich insights and narratives on disaster resilience policy and practice. It considers the possibilities for advancing community resilience and capacity building through an exploration of different aspects of governance and policy. Given the diversity of these countries and recent disasters, a variety of perspectives are considered: institutional and policy frameworks, risk management governance, recovery operations, building codes, and policy and media discourse. The book offers a collective understanding of practice, which can offer global lessons to a world increasingly beset by disasters and with uncertain environmental futures. This book will be a valuable resource for scholars, practitioners and students in the fields of disaster risk reduction and management, climate change adaptation, public policy and sustainable development.
The Kingdom of Hazrat Ali (R.A) is a golden and insightful book written to help the reader understand the great personality of one of the greatest companions of the Prophet Muhammad (P.B.U.H). It is essential to read any of your religious inclinations if you want to understand before, in time, the kingdom and the great contribution of Hazrat Ali to Islam and his particular inclination towards Islam. The oracle distinguishes him from all other companions. In addition to the historical facts, this book presents several lessons from his life that may inspire Muslims worldwide to become more committed, devoted, and loyal to the cause of Islam.
Few people are more important when establishing the caliphate and the Arab-Muslim Empire in the early phases of its existence. One of them is Mu' awiya ibn Abi Sufyan. There are a lot of controversies in Islam about this great man. But this is separate from the extraordinary achievements he made in his lifetime. Mu'awiya is a powerful figure in the history of Islam. Mu'awiya ibn Abi Sufyan is undoubtedly the most elusive and ambiguous of the early caliphs. Furthermore, he was a political genius at a time when nothing else could have saved the Islamic Empire from dissolution, regardless of what we think of him as a ruler and a man (a matter on which opinions disagree sharply, to put it gently). He goes through numerous stages in his life and work. There is a wealth of information on Mu' awiya ibn Abi Sufyan in this book, from his life and times in the Islamic Empire through his character, controversies, and reign.
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.